23 June 2025 ORYZON announces submission of Phase III protocol to FDA to initiate PORTICO-2 trial of vafidemstat in Borderline Personality Disorder (BPD) patients
17 June 2025 ORYZON to attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29
16-19 June 2025 BIO International Convention 2025 Boston Convention & Exhibition Center, Boston MA United States